Relevance of hypoxia in radiation oncology: Pathophysiology, tumorbiology and implications for treatment

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 3, 2013, Pages 219-234

  Busk, M ^a   Horsman, M R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Hypoxia, brain; Neoplastic cells, circulating; Radiotherapy

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; BANOXANTRONE; CARBOGEN; CARBONATE DEHYDRATASE IX; CISPLATIN; COPPER DIACETYL BIS(METHYLTHIOSEMICARBAZONE); DORANIDAZOLE; ERYTHROPOIETIN; ETANIDAZOLE; FLUOROAZOMYCIN ARABINOSIDE; GIRENTUXIMAB; GLUCOSE; HORMONE DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LACTIC ACID; MESSENGER RNA; MISONIDAZOLE; NICOTINAMIDE; NIMORAZOLE; NITROIMIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OSTEOPONTIN; PIMONIDAZOLE; RADIOSENSITIZING AGENT; TH 302; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANEMIA; BLADDER CARCINOMA; BLOOD TRANSFUSION; BLOOD VISCOSITY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DISEASE SEVERITY; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG BLOOD LEVEL; DRUG SAFETY; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HYPERBARIC OXYGEN; HYPERTHERMIC THERAPY; HYPOXIA; HYPOXIC CELL; IN VITRO STUDY; INTENSITY MODULATED RADIATION THERAPY; KIDNEY CARCINOMA; META ANALYSIS (TOPIC); METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; OXYGEN BREATHING; OXYGEN DIFFUSION; OXYGEN ENHANCEMENT RATIO; OXYGEN SUPPLY; OXYGEN TENSION; PANCREAS CANCER; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTON; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION INJURY; RADIOBIOLOGY; RADIOSENSITIVITY; RADIOSENSITIZATION; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REOXYGENATION; REVIEW; TISSUE OXYGENATION; TISSUE PRESSURE; TREATMENT OUTCOME; TUMOR BLOOD FLOW; TUMOR HYPOXIA; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA;

ANIMALS; CELL HYPOXIA; GENETIC THERAPY; HUMANS; HYPERBARIC OXYGENATION; MOLECULAR IMAGING; NEOPLASMS; OXYGEN; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, IMAGE-GUIDED; TUMOR MICROENVIRONMENT;

EID: 84888807825     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
3. Franko AJ, Sutherland RM. Oxygen diffusion distance and development of necrosis in multicell spheroids. Radiat Res 1979;79:439-53. (Pubitemid 9240801)
4. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
5. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10. (Pubitemid 37328844)
6. De PM, Lewis CE. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013;23:277-86.
7. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65. (Pubitemid 20008770)
8. Chaplin DJ, Durand RE, Olive PL. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 1986;12:1279-82. (Pubitemid 16030598)
9. Grotius J, Dittfeld C, Huether M, Mueller-Klieser W, Baumann M, Kunz-Schughart LA. Impact of exogenous lactate on survival and radioresponse of carcinoma cells in vitro. Int J Radiat Biol 2009;85:989-1001.
10. Zhu Y, Zhao T, Itasaka S, Zeng L, Yeom CJ, Hirota K et al. Involvement of decreased hypoxia-inducible factor 1 activity and resultant G1-S cell cycle transition in radioresistance of perinecrotic tumor cells. Oncogene 2013;32:2058-68.
11. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S et al. Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 2008;68:605-14. (Pubitemid 351380090)
12. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 1997;147:541-50. (Pubitemid 27204090)
13. Horsman MR, Nordsmark M, Khalil AA, Hill SA, Chaplin DJ, Siemann DW et al. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. Acta Oncol 1994;33:371-6. (Pubitemid 24207997)
14. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010;94:30-5.
15. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 2012;105:14-20.
16. Chaplin DJ, Horsman MR, Trotter MJ. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst 1990;82:672-6. (Pubitemid 20154274)
17. Horsman MR, Wood PJ, Chaplin DJ, Brown JM, Overgaard J. The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo. Radiother Oncol 1990;18:49-57. (Pubitemid 20174444)
18. Crokart N, Jordan BF, Baudelet C, Ansiaux R, Sonveaux P, Grégoire V et al. Early reoxygenation in tumors after irradiation: determining factors and consequences for radiotherapy regimens using daily multiple fractions. Int J Radiat Oncol Biol Phys 2005;63:901-10. (Pubitemid 41400082)
19. Olive PL. Radiation-induced reoxygenation in the SCCVII murine tumour: evidence for a decrease in oxygen consumption and an increase in tumour perfusion. Radiother Oncol 1994;32:37-46. (Pubitemid 24246762)
20. Dunst J, Hansgen G, Lautenschlager C, Fuchsel G, Becker A. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon. Int J Radiat Oncol Biol Phys 1999;43:367-73. (Pubitemid 29091478)
21. Achermann RE, Ohlerth SM, Rohrer Bley C, Gassmann M, Inteeworn N, Roos M et al. Oxygenation of spontaneous canine tumors during fractionated radiation therapy. Strahlenther Onkol 2004;180:297-305. (Pubitemid 38667750)
22. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M et al. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-andneck cancer. Radiother Oncol 2007;83:406-10. (Pubitemid 46915551)
23. Harriss W, Bezak E, Yeoh E, Hermans M. Measurement of reoxygenation during fractionated radiotherapy in head and neck squamous cell carcinoma xenografts. Australas Phys Eng Sci Med 2010;33:251-63.
24. Santiago A, Eicheler W, Bussink J, Rijken P, Yaromina A, Beuthien-Baumann B et al. Effect of cetuximab and fractionated irradiation on tumour micro-environment. Radiother Oncol 2010;97:322-9.
25. Stadler P, Feldmann HJ, Creighton C, Kau R, Molls M. Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. Radiother Oncol 1998;48:157-64. (Pubitemid 28423787)
26. Yaromina A, Kroeber T, Meinzer A, Boeke S, Thames H, Baumann M et al. Exploratory study of the prognostic value of microenvironmental parameters during fractionated irradiation in human squamous cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 2011;80:1205-13.
27. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck - a systematic review and meta-analysis. Radiother Oncol 2011;100:22-32.
28. Becker A, Kuhnt T, Liedtke H, Krivokuca A, Bloching M, Dunst J. Oxygenation measurements in head and neck cancers during hyperbaric oxygenation. Strahlenther Onkol 2002;178:105-8. (Pubitemid 34135518)
29. Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 2012;4:CD005007.
30. Hill SA, Collingridge DR, Vojnovic B, Chaplin DJ. Tumour radiosensitization by high-oxygen-content gases: influence of the carbon dioxide content of the inspired gas on P02, microcirculatory function and radiosensitivity. Int J Radiat Oncol Biol Phys 1998;40:943-51. (Pubitemid 28150813)
31. Dunn TJ, Braun RD, Rhemus WE, Rosner GL, Secomb TW, Tozer GM et al. The effects of hyperoxic and hypercarbic gases on tumour blood flow. Br J Cancer 1999;80:117-26. (Pubitemid 29210097)
32. Partridge SE, Aquino-Parsons C, Luo C, Green A, Olive PL. A pilot study comparing intratumoral oxygenation using the comet assay following 2.5% and 5% carbogen and 100% oxygen. Int J Radiat Oncol Biol Phys 2001;49:575-80. (Pubitemid 32120258)
33. Mortensen LS, Busk M, Nordsmark M, Jakobsen S, Theil J, Overgaard J et al. Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study. Radiother Oncol 2011;99:418-23.
34. Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC. Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Biol Phys 2009;73.1177-86.
35. Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 2012;30:1777-83.
36. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010;28:4912-8.
37. Kaanders JH, Stratford MR, Liefers J, Dennis MF, van der Kogel AJ, van Daal WA et al. Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. Radiother Oncol 1997;43:67-73. (Pubitemid 27191981)
38. Hoff CM. Importance of hemoglobin concentration and its modification for the outcome of head and neck cancer patients treated with radiotherapy. Acta Oncol 2012;51:419-32.
39. Stuben G, Thews O, Pottgen C, Knuhmann K, Vaupel P, Stuschke M. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-50. (Pubitemid 32453676)
40. Hoff CM, Lassen P, Eriksen JG, Hansen HS, Specht L, Overgaard M et al. Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? - Results from the randomized DAHANCA 5 and 7 trials. Acta Oncol 2011;50:1006-14.
41. Hoff CM, Hansen HS, Overgaard M, Grau C, Johansen J, Bentzen J et al. The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy - resuits from the randomized DAHANCA 5 study. Radiother Oncol 2011;98:28-33.
42. Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Wiirschmidt F et al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol 2011;29:3791-7.
43. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60. (Pubitemid 37324251)
44. Chan P, Milosevic M, Fyles A, Carson J, Pintilie M, Rauth M et al. A phase III randomized study of misonidazole plus radiation vs. radiation alone for cervix cancer. Radiother Oncol 2004;70:295-9. (Pubitemid 38520163)
45. Grigsby PW, Winter K, Wasserman TH, Marcial V, Rotman M, Cooper J et al. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1999;44:513-7. (Pubitemid 29258424)
46. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jørgensen K, Sandberg E et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989;16:1065-8. (Pubitemid 19154303)
47. Fazekas J, Pajak TF, Wasserman T, Marcial V, Davis L, Kramer S et al. Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck. Int J Radiat Oncol Biol Phys 1987;13:1155-60.
48. Murata R, Tsujitani M, Horsman MR. Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole. Radiother Oncol 2008;87:331-8.
49. Overgaard J, Overgaard M, Nielsen OS, Pedersen AK, Timothy AR. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer 1982;46:904-11. (Pubitemid 13177697)
50. Overgaard J, Overgaard M, Timothy AR. Studies of the pharmacokinetic properties of nimorazole. Br J Cancer 1983;48:27-34. (Pubitemid 13067942)
51. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46. (Pubitemid 28109172)
52. Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol (R Coll Radiol) 2007;19:418-26. (Pubitemid 46995618)
53. Vujaskovic Z, Poulson JM, Gaskin AA, Thrall DE, Page RL, Charles HC et al. Temperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment. Int J Radiat Oncol Biol Phys 2000;46:179-85. (Pubitemid 30021498)
54. Overgaard J, Poulsen HS. Effect of hyperthermia and environmental acidity on the proteolytic activity in murine ascites tumor cells. J Natl Cancer Inst 1977;58:1159-61. (Pubitemid 8073462)
55. Beck R, Roper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 2007;48:973-80. (Pubitemid 46909926)
56. Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989-95.
57. Ghatage P, Sabagh H. Is there a role for tirapazamine in the treatment of cervical cancer? Expert Opin Drug Metab Toxicol 2012;8:1589-97.
58. Williams KJ, Albertella MR, Fitzpatrick B, Loadman PM, Shnyder SD, Chinje EC et al. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts. Mol Cancer Ther 2009;8:3266-75.
59. Albertella MR, Loadman PM, Jones PH, Phillips RM, Rampling R, Burnet N et al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 2008;14:1096-104. (Pubitemid 351302556)
60. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 2012;18:758-70.
61. Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364-76.
62. Dubois L, Peeters S, Lieuwes NG, Geusens N, Thiry A, Wigfield S et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 2011;99:424-31.
63. Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2011;29:121-6.
64. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-60. (Pubitemid 30317470)
65. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:541-51. (Pubitemid 47380112)
66. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300. (Pubitemid 46589864)
67. Rudat V, Stadler P, Becker A, Vanselow B, Dietz A, Wannenmacher M et al. Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlenther Onkol 2001;177:462-8. (Pubitemid 32861426)
68. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24. (Pubitemid 41503384)
69. Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-56. (Pubitemid 28423786)
70. Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results. IntJ Radiat Oncol Biol Phys 2012;82.e433-e9.
71. Dellas K, Bache M, Pigorsch SU, Taubert H, Kappler M, Holzapfel D et al. Prognostic impact of HIF-lalpha expression in patients with definitive radiotherapy for cervical cancer. Strahlenther Onkol 2008;184:169-74. (Pubitemid 351365780)
72. Ogawa K, Chiba I, Morioka T, Shimoji H, Tamaki W, Takamatsu R et al. Clinical significance of HIF-lalpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. Anticancer Res 2011;31:2351-9.
73. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouyssegur J et al. HIF-lalpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 2007;120:1451-8. (Pubitemid 46355379)
74. Winter SC, Shah KA, Han C, Campo L, Turley H, Leek R et al. The relation between hypoxia-inducible factor (HIF)-lalpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006;107:757-66. (Pubitemid 44232668)
75. Xiang ZL, Zeng ZC, Fan J, Tang ZY, He J, Zeng HY et al. The expression of HIF-lalpha in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol Biol Rep 2012;39:2021-9.
76. Sørensen BS, Hao J, Overgaard J, Vorum H, Honoré B, Alsner J et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 2005;76:187-93. (Pubitemid 41725446)
77. Troost EG, Bussink J, Kaanders JH, van Eerd J, Peters JP, Rijken PF et al. Comparison of different methods of CALX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 2005;76:194-9. (Pubitemid 41725447)
78. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440:1222-6.
79. Le QT, Harris J, Magliocco AM, Kong CS, Diaz R, Shin B et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol 2009;27:4281-6.
80. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007;67:3441-9. (Pubitemid 46724885)
81. Toustrup K, Sorensen BS, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol 2012;22:119-27.
82. Toustrup K, Sorensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 2011;71:5923-31.
83. Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C et al. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer 2012;107:840-6.
84. Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D et al. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res 2012;18:301-7.
85. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005;6:757-64. (Pubitemid 41430716)
86. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
87. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F.fluoromisonidazole and [18F. fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52. (Pubitemid 38445681)
88. Busk M, Horsman MR, Kristjansen PE, van der Kogel AJ, Bussink J, Overgaard J. Aerobic glycolysis in cancers: implications for the usability of oxygen-responsive genes and fluorodeoxyglucose-PET as markers of tissue hypoxia. Int J Cancer 2008;122:2726-34. (Pubitemid 351631374)
89. Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys 2005;62:545-53. (Pubitemid 40704474)
90. Christian N, Deheneffe S, Bol A, De Bast M, Labar D, Lee JA et al. Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models. Radiother Oncol 2010;97:183-8.
91. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M et al. FDG - a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006;33:1426-31. (Pubitemid 44885408)
92. Busk M, Horsman MR, Overgaard J. Resolution in PET hypoxia imaging: voxel size matters. Acta Oncol 2008;47:1201-10.
93. Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA - first small animal PET results. J Pharm Pharm Sci 2007;10:203-11.
94. Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91. (Pubitemid 19279502)
95. Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori SY, Tona Y et al. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 2011;25:625-33.
96. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435-41. (Pubitemid 44497258)
97. Hugonnet F, Fournier L, Medioni J, Smadja C, Hindié E, Huchet V et al. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med 2011;52:1048-55.
98. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60. (Pubitemid 43073432)
99. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006;24:2098-104. (Pubitemid 46622121)
100. Zips D, Zöphel K, Abolmaali N, Perrin R, Abramyuk A, Haase R et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012;105:21-8.
101. Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. (1)(8) F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with (1)(8)F-FMISO. Nucl Med Commun 2012;33:1096-102.
102. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999;40:177-83. (Pubitemid 29044189)
103. Matsumoto K, Szajek L, Krishna MC, Cook JA, Seidel J, Grimes K et al. The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using 64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography. Int J Oncol 2007;30:873-81.
104. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493-502. (Pubitemid 40470433)
105. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42. (Pubitemid 350251048)
106. Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med 2013;54:201-7.
107. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging 2013;40:186-97.